The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of indoximod-based chemo-immunotherapy in patients with pediatric brain tumors on activation and clonal proliferation of a circulating population of early non-exhausted stem-like CD8+ T cells whose on-treatment expansion is predictive of long-term outcome.
 
Rafal Pacholczyk
No Relationships to Disclose
 
Sarthak Satpathy
No Relationships to Disclose
 
Zuzana Berrong
No Relationships to Disclose
 
Franklin Chien
Employment - Omeros (I)
Stock and Other Ownership Interests - Omeros (I)
 
Chenbin Huang
No Relationships to Disclose
 
Ramses F. Sadek
No Relationships to Disclose
 
Beena E. Thomas
No Relationships to Disclose
 
Christopher Smith
Employment - Lumos Pharma
Stock and Other Ownership Interests - Lumos Pharma
 
Tobey J. MacDonald
No Relationships to Disclose
 
Eugene Paul Kennedy
Employment - CSL Limited (I); Galera Therapeutics
Leadership - Galera Therapeutics
Stock and Other Ownership Interests - CSL Behring (I); Galera Therapeutics; Lumos Pharma
 
Theodore S. Johnson
Research Funding - Janssen Scientific Affairs; Lumos Pharma
 
Manoj K. Bhasin
Consulting or Advisory Role - Sanofi
 
David H. Munn
Stock and Other Ownership Interests - Lumos Pharma
Patents, Royalties, Other Intellectual Property - Patents and royalties regarding IDO-inhibitor drugs
(OPTIONAL) Uncompensated Relationships - Co-inventor on patents licensed to Lumos Pharma